Core Viewpoint - Shenghong Technology (300476.SZ) has announced the results of its private placement, with a determined issuance price of 248.02 CNY per share and a total fundraising amount of 1,899,999,869.44 CNY from the issuance of 7,660,672 shares [1]. Group 1: Issuance Details - The total number of shares issued is 7,660,672 [2][3]. - The total amount raised from this issuance is 1,899,999,869.44 CNY [1]. - The issuance price per share is set at 248.02 CNY [1]. Group 2: Subscription Breakdown - The top subscriber, Xingzheng Global Fund Management Co., Ltd., received 3,104,588 shares, amounting to 769,999,915.76 CNY, with a lock-up period of 6 months [2]. - China International Capital Corporation Limited subscribed for 1,060,398 shares, totaling 262,999,911.96 CNY, also with a 6-month lock-up period [2]. - UBS AG acquired 810,418 shares for 200,999,872.36 CNY, with a 6-month lock-up period [2].

证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.21亿元，其中，买入成交额为4161.81 万元，卖出成交额为7911.32万元，合计净卖出3749.50万元。 具体来看，第一大买入营业部及卖出营业部均为国泰海通证券股份有限公司总部，买入金额为1255.48 万元，卖出金额为3842.55万元。 近半年该股累计上榜龙虎榜5次，上榜次日股价平均跌2.42%，上榜后5日平均跌3.33%。 华新精科(603370)今日上涨0.13%，全天换手率25.83%，成交额4.91亿元，振幅4.91%。龙虎榜数据显 示，营业部席位合计净卖出3749.50万元。 上交所公开信息显示，当日该股因日换手率达25.83%上榜，营业部席位合计净卖出3749.50万元。 华新精科9月19日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 国泰海通证券股份有限公司总部 | 1255.48 | | | 买二 | 高盛(中国)证券有限责任公司上海浦东新区世纪大道证券 | 1094.57 | | | ...

本公司及其董事会全体成员保证公告内容的真实、准确和完整，不存在虚假记载、误导性陈述或重大遗 漏，并对其内容的真实性、准确性和完整性承担个别和连带的法律责任。 中国银河证券股份有限公司（以下简称"发行人"）面向专业投资者公开发行面值总额不超过200亿元 （含200亿元）的永续次级债券已于2025年8月13日获中国证券监督管理委员会出具的《关于同意中国银 河证券股份有限公司向专业投资者公开发行永续次级公司债券注册的批复》（证监许可〔2025〕1723 号）注册。 根据《中国银河证券股份有限公司2025年面向专业投资者公开发行永续次级债券（第一期）募集说明 书》，中国银河证券股份有限公司2025年面向专业投资者公开发行永续次级债券（第一期）（以下简 称"本期债券"）的发行规模不超过人民币50亿元（含50亿元），发行价格为每张人民币100元，采取网 下面向专业投资者簿记建档的方式发行。本期债券以每5个计息年度为1个重定价周期。在每个重定价周 期末，发行人有权选择将本期债券期限延长1个重定价周期（即延续5年），或全额兑付本期债券。 证券代码：601881 证券简称：中国银河 公告编号：2025-077 本期债券发行工作 ...

承销机构及其关联方参与了该期债券的认购。主承销商中信建投证券股份有限公司的关联方中信证券股 份有限公司及中信信托有限责任公司参与认购并分别获配该期债券金额人民币0.5亿元及人民币0.2亿 元，主承销商中国国际金融股份有限公司的关联方中国中金财富证券有限公司参与认购并获配该期债券 金额人民币1亿元，主承销商申万宏源证券有限公司的关联方富国基金管理有限公司参与认购并获配该 期债券金额人民币2.6亿元，主承销商光大证券股份有限公司的关联方交银国际信托有限公司参与认购 并获配该期债券金额人民币0.1亿元。 格隆汇9月18日丨中国银河(06881.HK)宣布，公司已于2025年9月18日完成2025年永续次级债券(第一期) 公开发行。该期债券的发行规模为人民币50亿元，发行价为每单位人民币100元。该期债券以每五个计 息年度为一个重定价周期，在每个重定价周期末，公司有权选择将该期债券期限延长一个重定价周期 (即延续五年)，或全额兑付该期债券。该期债券的首个重定价周期(前五个计息年度)的票面利率为 2.40%。该期债券发行所募集的资金将用於偿还该公司到期公司债券。 ...

Core Points - The company,稳健医疗, announced the listing of previously issued shares on September 12, with a total share capital of 582,329,808 shares, of which 407,246,427 shares are subject to restrictions, accounting for 69.93% of the total share capital [1] - The restricted shares to be listed amount to 406,614,387 shares, representing 69.8254% of the total share capital, with the listing date set for September 17, 2025 [1] - The sole shareholder applying for the lifting of restrictions is the controlling shareholder, 稳健集团有限公司, which has complied with all commitments made since the company's listing [2] Financial Summary - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on September 17, 2020, with an initial issuance of 50 million shares at a price of 74.30 yuan per share [2] - The total funds raised amounted to 3.715 billion yuan, with a net amount of 3.559 billion yuan after deducting issuance costs, exceeding the original plan by 2.133 billion yuan [2] - The funds were intended for projects including high-end dressing production line construction, marketing network development, research center establishment, and digital management system implementation [2] Underwriting and Dividend Information - The underwriting institution for the listing is China International Capital Corporation, with underwriting fees totaling 156 million yuan, of which 123 million yuan is allocated to the underwriting institution [3] - In the 2022 annual equity distribution announcement, the company proposed a cash dividend of 19.00 yuan (tax included) for every 10 shares, along with a capital increase of 4 shares for every 10 shares held [3]

9月11日，上交所官网披露了中电建新能源集团股份有限公司（以下简称"电建新能"）首次公开发行股票招股说明书（申报稿），电建新能IPO材料被正式受 理。 招股书显示，电建新能本次拟公开发行股票数量不低于8.33亿股且不超过25.00亿股（行使超额配售选择权前），占发行后总股本的比例不低于10%，且不高 于25%，拟于上交所主板上市，保荐机构为中金公司。 | 公司全称 | 中电建新能源集团股份有限公司 | 受理日期 | 2025-09-11 | | --- | --- | --- | --- | | 公司简称 | 电建新能 | 融资金额(亿元) | 90.00 | | 审核状态 | 已受理 | 更新日期 | 2025-09-11 | | 保荐机构 | 中国国际金融股份有限公司 | 保荐代表人 | 刘一飞,孟娇 | | 会计师事务所 | 信永中和会计师事务所(特殊普通合伙) | 签字会计师 | 詹军,吕相平 | | 律师事务所 | 北京市嘉源律师事务所 | 签字律师 | 黄国宝,齐曼 | | 评估机构 | 北京天健兴业资产评估有限公司 | 签字评估师 | 包迎春,邵伟伟 | 装机量方面，电建新能2022年底装机量为 ...

Core Viewpoint - The shareholder Shenzhen Koyi Pharmaceutical Holdings Co., Ltd. plans to transfer 10,062,800 shares of Sinovac Biotech, accounting for 5.00% of the company's total share capital, for its own operational development needs [1][2]. Group 1: Share Transfer Details - The transfer is a non-public transfer and will not be conducted through centralized bidding or block trading, meaning it is not a secondary market reduction [2][3]. - The transferee must be an institutional investor with appropriate pricing capability and risk tolerance [2]. - As of September 12, 2025, Koyi Pharmaceutical holds 119,751,430 shares, representing 59.50% of the company [2]. Group 2: Previous Share Transfers - On July 30, 2025, Koyi Pharmaceutical had previously planned to transfer 6,037,717 shares, which accounted for 3.00% of the total share capital, also for funding needs [3]. - The transfer price for the previous transaction was set at 36.70 CNY per share, totaling approximately 221.58 million CNY [3]. - Koyi Pharmaceutical had reduced its holdings by 5,989,200 shares between June 26 and July 9, 2025, at prices ranging from 32.84 to 48.37 CNY per share, amounting to a total of approximately 220.99 million CNY [3][4]. Group 3: Company Financials and Future Plans - Sinovac Biotech was listed on the Shanghai Stock Exchange on December 14, 2020, with an initial public offering (IPO) price of 22.33 CNY per share, raising a total of 1.11 billion CNY [4]. - The actual net fundraising was 995 million CNY, which was 710 million CNY less than the originally planned amount of 1.705 billion CNY [4]. - The company is currently planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with relevant intermediaries [5].

Core Viewpoint - The announcement details a share transfer plan by Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. to transfer 10,062,800 shares of Kexing Pharmaceutical, representing 5.00% of the total share capital, through a non-public inquiry transfer process [3][7]. Group 1: Share Transfer Details - The total number of shares to be transferred is 10,062,800, which accounts for 5.00% of the company's total share capital [3][7]. - The transfer is organized by China International Capital Corporation (CICC) and is not conducted through public trading methods [3][10]. - The receiving party must be an institutional investor with appropriate pricing capabilities and risk tolerance [3][10]. Group 2: Seller Information - The seller, Shenzhen Keyi Pharmaceutical, is the controlling shareholder of Kexing Pharmaceutical, with a shareholding exceeding 5% [3][4]. - The seller has confirmed that the shares are free from any transfer restrictions and have been released from lock-up [4][5]. Group 3: Pricing Mechanism - The minimum transfer price will not be lower than 70% of the average trading price of the company's shares over the 20 trading days prior to the issuance of the subscription invitation [8]. - The pricing determination will follow a priority system based on subscription price, quantity, and time of submission [9]. Group 4: Company Status - Kexing Pharmaceutical does not have any undisclosed operational risks or potential changes in control related to this share transfer [11]. - There are no other significant undisclosed matters concerning the company [11].

Core Viewpoint - The article discusses the acquisition process of Sichuan Chengyu Highway Co., Ltd. by Shudao Investment Group, highlighting the compliance with regulatory requirements and the ongoing supervision by China International Capital Corporation (CICC) as the financial advisor [1][4]. Group 1: Acquisition Overview - Shudao Group acquired a total of 1,096,769,662 shares of Sichuan Chengyu, representing a 35.86% stake, following the merger of Sichuan Transportation Investment Group and Sichuan Railway Industry Investment Group [1]. - The acquisition was facilitated through a series of agreements signed between the involved parties, including the asset transfer agreement [1][2]. Group 2: Regulatory Compliance - Shudao Group received a written approval from the Hong Kong Securities and Futures Commission for the exemption from making a mandatory offer due to the nature of the asset transfer [2]. - Sichuan Chengyu has consistently fulfilled its reporting and announcement obligations throughout the acquisition process, including multiple disclosures on the Shanghai Stock Exchange [2][3]. Group 3: Ongoing Supervision - CICC has issued a continuous supervision opinion confirming that the asset transfer registration procedures have been completed and that the involved parties have adhered to disclosure obligations [4]. - The financial advisor has verified that there have been no violations of commitments made by Shudao Group during the supervision period [6]. Group 4: Future Plans and Commitments - Shudao Group has no plans to change the main business operations of Sichuan Chengyu in the next 12 months, nor does it intend to make significant adjustments to the company's assets or management [7][8][9]. - There are no plans for major changes to the company's articles of association or employee hiring practices during the supervision period [10][11]. Group 5: Corporate Governance - Sichuan Chengyu has established a sound corporate governance structure and internal control system, complying with the relevant regulations set by the China Securities Regulatory Commission [12]. - The company has maintained independent operations of its general meetings, board of directors, and supervisory board, with no significant violations of governance regulations identified [12]. Group 6: Other Obligations - There are no additional obligations from the acquisition that Shudao Group has failed to fulfill, indicating compliance with all stipulated requirements [14].

Core Viewpoint - The company, China International Capital Corporation (CICC), is experiencing a projected significant increase in net profit for the first quarter of 2025, with expectations of a growth rate between 50% to 70% compared to the previous year [3]. Company Overview - CICC is a state-owned enterprise controlled by Central Huijin Investment Ltd, and it operates primarily in investment banking, wealth management, and asset management [2][3]. - The company was established on July 31, 1995, and listed on November 2, 2020, with its main business segments including investment banking, equity sales and trading, fixed income, wealth management, and investment management [7]. Financial Performance - For the first half of 2025, CICC reported a net profit of 4.33 billion yuan, representing a year-on-year increase of 94.35% [8]. - The projected net profit for the period from January 1, 2025, to March 31, 2025, is estimated to be between 1.858 billion yuan and 2.106 billion yuan, compared to 1.239 billion yuan in the same period last year [3]. Shareholder and Market Activity - As of June 30, 2025, the number of shareholders decreased by 11.17% to 124,000, while the average number of circulating shares per person increased by 12.62% to 23,649 shares [8]. - The company has distributed a total of 4.924 billion yuan in dividends since its A-share listing, with 2.607 billion yuan distributed over the past three years [9]. Institutional Holdings - As of June 30, 2025, major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 21.63 million shares, and Huatai-PB CSI 300 ETF, which also saw an increase in holdings [10].